Navigation Links
Nature's Bioceuticals Enters Chronic Obstructive Pulmonary Disease Market After Acquiring Breakthrough Breathing Formula

CAPE CORAL, Fla., Oct. 28, 2011 /PRNewswire/ -- Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures (, has entered into the $8.4 billion market chronic obstructive pulmonary disease market (COPD) with the completed acquisition of a ground breaking Breathing Formula. This all natural, non-synthetic, medicine was developed for the treatment of COPD, the two most common forms of which are Emphysema and Chronic Bronchitis. We believe that there is no other product currently available that can achieve the same results.

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, through 2019, an expanding aging population and increases in diagnosis and drug treatment will fuel steady 4.6 percent annual growth in the chronic obstructive pulmonary disease (COPD) drug market.

The Pharmacor 2010 findings from the topic titled Chronic Obstructive Pulmonary Disease reveal that the COPD drug market, which totaled nearly $8.4 billion in 2009, will reach more than $13 billion in 2019 in the USA, France, Germany, Italy, Spain, UK and Japan. The findings also reveal that the drug-treated COPD population will increase by nearly 6 million patients over the next decade. Although two maintenance therapies currently dominate the COPD market—GlaxoSmithKline's Advair/Seretide/Adoair and Boehringer Ingelheim/Pfizer's Spiriva—the near-term market will become fractured owing to the launch of new agents and generic erosion of key brands.

COPD is the fastest growing cause of death in the world's advanced economies. Such is the scale of the disease that the World Health Organization predicts it will be the third leading cause of death in the developed world by the year 2020 – faster growing than lung cancer, heart disease and stroke. The disease has reached epidemic proportions. It is estimated that up to 600 million people may suffer from COPD worldwide.

Robert deZanger, CEO of Nature's Bioceuticals states, "We are excited to roll out our COPD formula. The market for our product is immense and the need is great. People afflicted with COPD have been prescribed repurposed asthma medicines to help them breathe. Our product should provide "natural relief", without the harmful side effects, to millions of people with chronic breathing problems."  

Nature's Bioceuticals management is currently determining whether to go through the time and expense of filing an Investigational New Drug (IND) Application and New Drug Application with the FDA for approval as a drug or to market the Formula as a nutritional supplement under the Dietary Supplement Health and Education Act of 1994 (DSHEA). If the formula is marketed under DSHEA the company will not be able to make any claims about the product treating, preventing or curing COPD or any disease.

If the product is marketed under DSHEA we expect revenues to exceed $12 million year one during ramp up and $40 million year two as we gain market share.

About Nature's Bioceuticals;Nature's Bioceuticals develops and acquires the rights to natural medicine formulas that are geared towards treating specific medical conditions. These medicines are all natural and derived from botanicals and mineral bases. Nature's Bioceuticals strives to provide high quality natural medicines that are as effective, if not more effective, than synthetic drugs and more importantly do not have the negative side effects usually associated with many of today's prescribed drugs.

Nature's line of natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA, or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, commonly referred to as "DSHEA"

In addition to historical information, this release contains forward-looking statements. Mistral Ventures, Inc. and/or Nature's Bioceuticals may, from time to time, make written or oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements encompass Mistral Ventures, Inc. and/or Nature's Bioceuticals beliefs, expectations, hopes, or intentions regarding future events. Words such as "expects," "intends," "believes," "anticipates," "should," "likely," and similar expressions identify forward-looking statements. All forward-looking statements included in this release are made as of the date hereof and are based on information available to the Company as of such date. Neither Mistral Ventures, Inc. nor Nature's Bioceuticals assume any obligation to update any forward-looking statement. Actual results will vary, and may vary materially, from those anticipated, estimated, projected or expected for a number of reasons, including, among others: further reviews of the Company's financial statements by the Company and its Audit Committee; modification of the Company's accounting practices; foreign business risks; industry cyclicality; fluctuations in customer demand and order pattern; changes in pricing and general economic conditions; as well as other risks that may be delineated from time to time or filed with the SEC.Media Contact:Financial InsightPhone Number: 888 656 3509E-mail:

SOURCE Nature's Bioceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. James L. Wittliff, Ph.D., FACB, to Present Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System at the Association for Molecular Pathology Conference, October 30
2. Chromos enters into an Arrangement Agreement
3. American Laser Centers Opens Three Minneapolis-St. Paul Area Clinics
4. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
5. Melior Enters Research Collaboration with AstraZeneca
6. Truman Medical Centers Becomes One of the First Hospitals in the U.S. To Install the Worlds First Adaptive 128-slice CT Scanner
7. Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xian Qinba Xintong Medical Ltd.
8. Neptune Krill Oil, NKO(R), enters WALGREENS, the largest U.S. retail pharmacy chain, under the brand name Schiff(R) MegaRed(TM)
9. China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
10. NSF awards 14 materials research science and engineering centers
11. China Biologic Products Enters Into Agreement to Acquire 35% Interest in Xian Huitian Blood Products Co., Ltd. and Introduces Preliminary Guidance for 2009
Post Your Comments:
(Date:10/12/2015)... , Oct. 12, 2015  Patara Pharma, ... allergic and inflammatory diseases and conditions, today announced ... preferred stock financing. Concurrent with the close of ... into a Loan and Security Agreement with Silicon ... to $7 million. Patara will use the funds ...
(Date:10/12/2015)... October 12, 2015 ... version for enriched online experience --> ... to print version for enriched online experience ... media alternative to print version for enriched online ... of scientific, technical and medical information products and services, ...
(Date:10/12/2015)... ... October 12, 2015 , ... ... Dr. Srini Srinivasan, has joined the firm as a Premier Expert consultant. ... enable them to bring extraordinary value to the company's clients. Premier Experts ...
(Date:10/12/2015)... (PRWEB) , ... October 12, 2015 , ... LifeTrak ... the launch of LifeTrak Zoom, the world’s first amphibious fitness tracker that seeks to ... offers flexwear technology and accurate heart rate monitoring both in water and ...
Breaking Biology Technology:
(Date:9/30/2015)... Sept. 30, 2015  With nearly 300,000 Americans living ... new SCIs estimated to reach 12,500 annually, the role ... Resource Services for Independent Living (SCRS-IL) is increasingly ... California opening doors to independence for ... and services, notably assistive technology services and education. ...
(Date:9/29/2015)... Calif. , Sept. 29, 2015 ... improves employee productivity while also saving energy , ... such as Low Power Active Mode and embedded Fujitsu ... transformation Fujitsu today shows that good ... new and refreshed models to its enterprise desktop and ...
(Date:9/28/2015)... 28, 2015  The monitoring of vital signs, ... temperature, is an essential component of patient assessment. ... deterioration in a patient,s condition. However, in general ... typically taken during routine observation rounds only once ... deteriorates between these observation rounds, the warning signs ...
Breaking Biology News(10 mins):